ProGenis Pharmaceuticals is focused on developing next generation RNA therapeutics including splice switching antisense oligonucleotide drugs that are more efficient, safer and accessible to treat inherited rare and acquired diseases. ProGenis is headquartered in Perth, Australia, and led by world-renowned experts with significant experience in RNA therapeutics including antisense oligonucleotide chemistries and manufacturing.
As a leading innovator in the field of precision RNA therapy, our primary focus is on leveraging state-of-the-art antisense technology to provide highly effective treatments for a diverse array of acquired and genetic illnesses.
Our approach to precision RNA therapy represents a paradigm shift in the way we think about treating diseases.
Rather than relying on broad-spectrum drugs that target entire pathways or systems, we focus on directly addressing the underlying mechanisms of disease, delivering targeted treatments that are both highly effective and minimally invasive.
ProGenis is focused on tackling both acquired and genetic diseases through innovative drugs to bring change to the life quality of patients. Through our pioneering efforts, we are at the forefront of revolutionizing the way diseases are treated, offering new hope to patients suffering from previously untreatable conditions.
Through extensive research and analysis, we have identified a number of promising targets that have the potential to revolutionize the way we approach the treatment of a wide range of diseases.
*By submitting your information, you are granting us permission to email you. You may unsubscribe at any time.
